Home Cart Sign in  
Chemical Structure| 1990504-34-1 Chemical Structure| 1990504-34-1

Structure of Bomedemstat
CAS No.: 1990504-34-1

Chemical Structure| 1990504-34-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: IMG-7289

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bomedemstat

CAS No. :1990504-34-1
Formula : C28H34FN7O2
M.W : 519.61
SMILES Code : O=C(N[C@@H](CCCN[C@H]1[C@H](C2=CC=C(F)C=C2)C1)C(N3CCN(C)CC3)=O)C4=CC=C(N5N=NC=C5)C=C4
Synonyms :
IMG-7289
MDL No. :MFCD34602471

Safety of Bomedemstat

Related Pathways of Bomedemstat

epigenetics
GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6NJ mice RP-48OVA-LLO190 syngeneic tumor model Oral gavage 45 mg/kg/d daily, throughout the treatment To assess whether LSD1 inhibition with bomedemstat would enhance anti-tumor immune responses to RP-48OVA-LLO190 flank tumors grown in syngeneic C57BL6 recipient animals. Treatment with bomedemstat or anti-PD1 antibody alone exerted minimal growth suppressive effect while treatment with bomedemstat in combination with anti-PD1 antibody significantly suppressed growth, suggesting the possibility that LSD1 inhibition was augmenting anti-tumor immunity. PMID: 35920742
NSG mice FHSC04 PDX model tumors Oral gavage 25 mg/kg daily Bomedemstat treatment upregulates NOTCH and suppresses ASCL1 targets in human and murine SCLC models. PMID: 35920742
NSG mice FHSC04 PDX model tumors Oral gavage 40 mg/kg on days 1-5 of a 7-day cycle Bomedemstat treatment upregulates NOTCH and suppresses ASCL1 targets in human and murine SCLC models. PMID: 34927013
C57BL/6 mice Mice bearing subcutaneous MV4–11 tumors Oral 7.5–15 mg/kg/day 21 days To measure intratumoral accumulation of bomedemstat. Significant intratumoral accumulation of orally-administered bomedemstat was measured with micromolar levels achieved in vivo. PMID: 38619005
C57BL/6 mice Normal mice Oral 40, 50, or 60 mg/kg/day 7 days To assess the hematopoietic effects of bomedemstat. Bomedemstat induced dose-dependent decreases in platelets, reticulocytes, and RBCs, but effects were reversible upon cessation of treatment. PMID: 38619005
Mx1cre-Jak2V617F mice Jak2V617F mouse model Oral gavage 45 mg/kg once daily for 14, 42, or 56 consecutive days IMG-7289 normalized neutrophil count within 14 days and significantly reduced WBC count, hematocrit, reticulocytosis, and monocytosis. PMID: 31723778
MPLW515L mice MPLW515L mouse model Oral gavage 15 mg/kg once daily for 42 days At the chosen dose of 45?mg/kg per d of IMG-7289, platelet counts were dramatically decreased. PMID: 31723778

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.62mL

1.92mL

0.96mL

19.25mL

3.85mL

1.92mL

 

Historical Records

Categories